Division of Movement Disorders

Print Friendly

Welcome to the USF Health Byrd
Parkinson’s Disease & Movement Disorders Center

Visit us at our new location!

USF Health Byrd Institute
4001 Fletcher Avenue , Suite 620

Tampa, FL 33613

Map & Directions

 

The USF Health Byrd Parkinson’s Disease and Movement Disorders Center is recognized by the National Parkinson Foundation as a Center of Excellence, serving over 5000 patients in Hillsborough, Pinellas, Pasco, Hernando, Manatee, Sarasota, Polk, and Orange counties. The Center provides expert evaluation and management for individuals with Parkinson’s disease, tremor, dystonia, restless legs syndrome and a variety of other movement disorders. Botulinum toxin injections are performed for cervical dystonia, blepharospasm, hemifacial spasm, limb dystonia and spasticity.


We are currently accepting new patients!
To make an appointment please call 813-396-0751.


 

 

Recent and Upcoming Events:

 "Inspire" 2013 Annual Gala

  Click Here for highlights from the event!!

  

 

Recent Publications

  1. Hauser RA, Hsu A, Kell S, Espay Al, Sethi K, Stacy M, Ondo W, O'Connell M, Gupta S; IPX066 ADVANCE-PD investigators. Extended-release carbidopa-Ievodopa (IPX066) compared with immediate-release carbidopa-Ievodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013 Apr;12(4):346-56. doi: 10.1016/51474-4422(13)70025-5. Epub 2013 Feb 26. PubMed PMID: 23485610.
  2. Hauser RA, Lyons KE, Pahwa R. The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. Int J Neurosci. 2012 Jul;122(7):333-7. doi: 10.3109/00207454.2012.657381. Epub 2012 Feb 23. PubMed PMID: 22329569.
  3. Hauser RA. Future treatments for Parkinson's disease: surfing the PD pipeline. Int J Neurosci. 2011;121 Suppl 2:53-62. doi: 10.3109/00207454.2011.620195. Review. PubMed PMID: 22035030.
  4. Hauser RA, Auinger P; Parkinson Study Group. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord. 2011 Apr;26(5):813-8. doi: 10.1002/mds.23638. Epub 2011 Mar 24. PubMed PMID: 21437987.
  5. Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. J Neuroimaging. 2012 Jul;22(3):225-30. doi: 10.1111/j.1552-6569.2011.00583.x. Epub 2011 Mar 16. Review. PubMed PMID: 21410815.
  6. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011 Mar;10(3):221-9. doi: 10.1016/51474-4422(11)70012-6. PubMed PMID: 21315654.
  7. Hauser RAJ Schapira AH, Rascol 0, Barone P, Mizuno V, Salin L, Haaksma M, Juhel NJ Poewe W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317. PubMed PMID: 20669317.
  8. Hauser RA, Auinger P, Oakes D; Parkinson Study Group. Levodopa response in early Parkinson's disease. Mov Disord. 2009 Dec 15;24(16):2328-36. doi: 10.1oo2/mds.22759. PubMed PMID: 19908302.
  9. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15;24(4):564-73. doi: 10.1002/mds.22402. PubMed PMID: 19086083.
  10. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group. Double-blind trial of levodopa/carbidopa/entacapone versus levodopajcarbidopa in early Parkinson's disease: Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343. PubMed PMID: 19058133.
  11. Hauser RA, Shulman LM, Trugman JM, RobertsJW, Mori A, Ballerini R, Sussman NM; Istradefylline 6002-US-013 Study Group. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008 Nov 15;23(15):2177-85. doi: 10.1002jmds.22095. PubMed PMID: 18831530.
  12. Hauser RA, Rascol 0, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007 Dec;22(16):2409-17. PubMed PMID: 17894339.
  13. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006 Dec;63(12):1756-60. PubMed PMID: 17172616.
  14. Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology. 2006 May 23;66(10 SuppI4):S58-68. PubMed PMID: 16717253.
  15. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord. 2004 Dec;19(12):1409-13. PubMed PMID: 15390057.
  16. Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003 Aug 12;61(3):297-303. PubMed PMID: 12913187.
  17. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CWo Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol.1999 Feb;56(2):179-87. PubMed PMID: 10025423.